Therapy Selection for ESA Ineligible LR-MDS Patients

MT-303, a novel GPC3-targeting mRNA/lipid nanoparticle chimeric antigen receptor therapy, enhances cytokine-driven immune response and tumor cytotoxicity.

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid tumors and multiple myeloma.

The 0.09 mg/kg dose group of the phase 1 dose-escalation portion of the Acclaim-3 study in extensive-stage small cell lung cancer is completed.

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with pembrolizumab.

The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been dosed.